Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
China flag China · Delayed Price · Currency is CNY
1.360
+0.020 (1.49%)
Aug 10, 2026, 3:00 PM CST

Kangmei Pharmaceutical Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
5,0335,2525,1894,8744,1804,153
Revenue Growth
-4.81%1.22%6.46%16.60%0.66%-23.27%
Gross Profit
951.36948.5653.37728.86431.1491.52
Operating Income
-251.88-221.55-413.53179.59-1,040-3,046
Net Income
-14.7410.338.57102.52-2,6887,918
Earnings Per Share
-0.000.000.000.01-0.190.57
EPS Growth
-16.67%-94.00%---

Revenue by Segment

Fiscal YearFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '24 Dec '23 Dec '22 Dec '21
Traditional Chinese Medicine, Western Medicine and Medical Devices
4,2194,2413,8763,4343,407
Health Food and Food
500.27437.48502.79324.58184.23
Property Leasing and Sales and Others
532.62510.55494.89421.95560.99
Total
5,2525,1894,8744,1804,153

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,2291,240977.921,0571,5082,419
Total Debt
173.71184.36139.13255.01263.87205.29
Net Cash (Debt)
1,0551,056838.8801.681,2442,214
Net Cash Growth
41.14%25.87%4.63%-35.54%-43.82%-
Net Cash Per Share
0.060.070.060.080.090.16

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
157.98111.35-427.63-317.52-749.96214.21
Capital Expenditures
-225.48-217.06-61.71-99.74-48.12-171.63
Free Cash Flow
-67.5-105.71-489.34-417.27-798.0842.58
Free Cash Flow Growth
------94.16%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
18.90%18.06%12.59%14.95%10.31%2.20%
Operating Margin
-5.00%-4.22%-7.97%3.69%-24.89%-73.37%
Pretax Margin
0.33%0.82%0.67%2.26%-63.73%196.39%
Profit Margin
-0.29%0.20%0.17%2.10%-64.31%190.68%
FCF Margin
-1.34%-2.01%-9.43%-8.56%-19.09%1.03%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-2557.443783.85251.53-5.41
Forward PE
-2.562.562.562.562.56
P/FCF Ratio
-----1006.12
PS Ratio
3.685.036.255.297.3010.32